AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter...
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia...
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.56%. December...
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.74%. December E-mini S&P...
/Alphabet%20Inc_%20and%20Google%20logos%20by%20IgorGolovinov%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is up by +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.60%. December E-mini S&P futures...
Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
Agios Pharmaceuticals: Q3 Earnings Snapshot